Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study

Enrico Smeraldi

Research output: Contribution to journalArticle

Abstract

In a multicentre, double blind, parallel group study 281 patients with DSM III-R diagnosis of dysthymia or a single episode of major depression in partial remission were randomised to 3 months of treatment with amisulpride 50 mg/day or fluoxetine 20 mg/day. The baseline Montgomery and Asberg Depression Rating Scale (MADRS) total score was reduced by at least 50% in 74.1% of patients (103/139) with amisulpride and 67.4% (87/129) with fluoxetine (P=0.230). No significant differences between treatment groups were found in the reductions in mean total score with the MADRS, Widlocher psychomotor retardation scale, Sheehan disability scale, and CGI. Anxiety measured by HAM-A total mean score decreased significantly more with amisulpride (63%) than with fluoxetine (54%; P = 0.021). There were 13 dropouts due to adverse events with amisulpride and ten with fluoxetine. The number of patients reporting at least one adverse event was similar in the two groups (amisulpride 47.5%; fluoxetine 40.9%). As expected, in the amisulpride group endocrine-like adverse events in female patients were the most common, while nausea, dyspepsia, anorexia and insomnia occurred more frequently with fluoxetine.

Original languageEnglish
Pages (from-to)47-56
Number of pages10
JournalJournal of Affective Disorders
Volume48
Issue number1
DOIs
Publication statusPublished - Feb 1 1998

Keywords

  • Amisulpride
  • Dsthymia
  • Flouxetine
  • Major depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Fingerprint Dive into the research topics of 'Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study'. Together they form a unique fingerprint.

  • Cite this